Sonnet Biotherapeutics Holdings Inc (NQ: SONN )
0.8600
+0.0098
(+1.15%)
Streaming Delayed Price
Updated: 3:52 PM EDT, Jul 26, 2024
Add to My Watchlist
Press Releases about Sonnet Biotherapeutics Holdings Inc
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split
September 16, 2022
Via ACCESSWIRE
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
Via AccessWire
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
May 10, 2022
Via AccessWire
Exposures
Product Safety
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update
February 08, 2022
Via AccessWire
Exposures
Product Safety
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg?v=0)
Via AccessWire
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/18777.jpg)
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
August 19, 2021
Via AccessWire
Topics
Regulatory Compliance
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.